Northwestern University Feinberg School of Medicine
Skip to main content

Mrksich Named Associate Director for Research Technology and Infrastructure at the Lurie Cancer Center

Milan Mrksich, PhD, has been appointed Associate Director for Research Technology and Infrastructure at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Mrksich is the Henry Wade Rogers Professor of Biomedical Engineering, Chemistry and Cell and Molecular Biology, with appointments in the McCormick School of Engineering and Applied Science, Weinberg College of Arts and Sciences, and Feinberg School of Medicine. In addition, Mrksich is Director of the new Center for Synthetic Biology, making Northwestern University one of the country’s top destinations in the field for research and education.

Dr. Mrksich will report to Lurie Cancer Center Director, Leonidas Platanias, MD, PhD, in this new role, and will be responsible for oversight of the Lurie Cancer Center’s research shared resource facilities. Currently, 15 shared resource facilities are supported by the Lurie Cancer Center, including the Center for Advanced Microscopy, Medicinal & Synthetic Chemistry Core, Targeted Transgenic & Mutagenesis Laboratory, and the High Throughput Analysis Laboratory.

As Associate Director for Research Technology and Infrastructure, Dr. Mrksich will assess existing needs and priorities, and facilitate the development of new shared facilities to support the research initiatives of Lurie Cancer Center investigators. In addition, he will provide leadership for the development of innovative research tools and technologies.

“Milan is a highly distinguished scientist and will play a key role in the expansion and strengthening of the Lurie Cancer Center’s research capabilities,” said Dr. Platanias. “I am delighted that he has joined our Senior Leadership.”

“I am very pleased to join the Lurie Cancer Center’s leadership team,” said Dr. Mrksich. “The Lurie Cancer Center has always been a leader in bringing new technologies to advance the diagnosis and treatment of cancer, and I’m excited to bring tomorrow’s technologies to our community of researchers and clinicians.”

Mrksich received his PhD in organic chemistry from the California Institute of Technology, and was a Howard Hughes Medical Institute Investigator (HHMI) from 2005 to 2013. With laboratories on both the Evanston and Chicago campuses of Northwestern University, Mrksich’s research combines synthetic chemistry with materials science to study important problems in cell biology. He is a co-founder of Arsenal Medical Inc., a medical devices company that has a stent product in clinical trials, and recently co-founded SAMDI Tech, an early-stage technology company based on his new platform for analyzing biochemical reactions.

Back to top